| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Talphera, Inc.$1.46
+0.14 (+10.29%)
C 50Pipeline Score Undervalued Pharma · Clinical
Market Cap
42.30 M
EPS
-0.30
P/E Ratio
-
Value Trade
109.95 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
-
R&D Expenses
1.65 M
Operating CF
-3.40 M
Total Assets
30.16 M
Total Liabilities
11.68 M
Equity
18.48 M
D/E Ratio
12,345
-8.44 %
Week
7.25 %
1 Month
2.66 %
3 Month
-36.81 %
6 Month
-96.91 %
5 Year
-99.18 %
All Time
Cash Data
Cash Position
21.11 M
Monthly Burn
1.13 M
Runway
16.9 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
1.23 M
52 Week Range
0.38 - 1.57
% held by Insiders
25.69 %
% held by Institutions
35.41 %
Enterprise Value
27.69 M
Total Shares
46.64 M
Short %
2.06 %
Float Shares
27.33 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Talphera, Inc.
332Total events
2Upcoming
96Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 2
Event history 330
May 13, 2026
◆Quarterly UpdateCorporate
First quarter 2026 financial results release and corporate update call
Q2 2026
◆FDA ApprovalNiyadApprovedFDA Decision
Planned approval of Niyad PMA in second half of 2026
anticoagulation for CRRTsource ↗
Mar 30, 2026
◆Poster PresentationnafamostatPresentation
Poster presentation on in vivo assessment of nafamostat in porcine model at AKI & CRRT 2026
anticoagulation during CRRT in a porcine model of AKIsource ↗
Mar 29, 2026
◆Poster PresentationNiyadApprovedPresentation
Poster presentation on NEPHRO-CRRT study design at AKI & CRRT 2026
anticoagulation during continuous renal replacement therapy (CRRT)source ↗
Mar 25, 2026
◆Enrollment UpdateNiyadApprovedTrial
Enrolling patients in NEPHRO-CRRT registrational study
anticoagulation during CRRTsource ↗
Mar 23, 2026
◆R&D DayNiyadApprovedPresentation
Virtual investor and analyst event on Niyad for CRRT
continuous renal replacement therapy (CRRT)source ↗
Mar 2, 2026
▲Enrollment MilestoneNiyadApprovedTrial
50% enrollment milestone achieved (35 of 70 patients)
anticoagulant for continuous renal replacement therapy (CRRT)source ↗
Mar 2026
▲Enrollment MilestoneNiyadApprovedTrial
35-patient enrollment milestone (50% enrollment) in NEPHRO CRRT study
anticoagulant for continuous renal replacement therapy (CRRT)source ↗
Mar 2026
●Poster PresentationNiyadApprovedPresentation
Two posters presented at AKI & CRRT 2026 conference
anticoagulant for CRRTsource ↗
Mar 2026
Drug Pipeline Intelligence
C50
Pipeline Score $359M
Pipeline ValueUndervalued
Valuation Signal6
Drugs Scored8.5x
rNPV / MCap Top 75%
Micro Cap (rank 229 of 911)
Percentile RankTalphera, Inc. carries a moderate pipeline score (50/100), with $6.4B risk-adjusted pipeline value, led by sufentanil in Moderate-to-severe Acute Pain (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sufentanil Small molecule | Moderate-to-severe Acute Pain | Phase 3 | NCT02447848 | 49% | $3.0B | COMPLETED | 76 | - | - | Jul 1, 2016 | - | Oct 19, 2017 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ARX-04 | moderate-to-severe acute pain | Phase 3 | 2016-09-15 | 63% of all patients had no adverse events; 90% of healthcare professionals and 87% of patients responded 'good' or 'excellent'; mean pain score of 6.2 at baseline; 27%, 49%, and 57% reductions in mean pain intensity at 1 hour, 2 hours, and 12 hours, respectively Read More | AcelRx Reports Positive Results for ARX-04 (sufentanil sublingual tablet, 30 mcg), Including in Elderly Patients and Patients with Organ Impairment, in Third Phase 3 Registration Trial, SAP303 Majority of Patients Had No Read More | |
ARX-04 | moderate-to-severe acute pain | Phase 3 | 2016-09-15 | 63% of all patients had no adverse events; 90% of healthcare professionals and 87% of patients responded 'good' or 'excellent'; mean pain score of 6.2 at baseline; 27%, 49%, and 57% reductions in mean pain intensity at 1 hour, 2 hours, and 12 hours, respectively Read More | AcelRx Reports Positive Results for ARX-04 (sufentanil sublingual tablet, 30 mcg), Including in Elderly Patients and Patients with Organ Impairment, in Third Phase 3 Registration Trial, SAP303 Majority of Patients Had No Read More | |
ARX-04 | moderate-to-severe acute pain | Phase 3 | 2016-09-15 | 63% of all patients had no adverse events; 90% of healthcare professionals and 87% of patients responded 'good' or 'excellent'; mean pain score of 6.2 at baseline; 27%, 49%, and 57% reductions in mean pain intensity at 1 hour, 2 hours, and 12 hours, respectively Read More | AcelRx Reports Positive Results for ARX-04 (sufentanil sublingual tablet, 30 mcg), Including in Elderly Patients and Patients with Organ Impairment, in Third Phase 3 Registration Trial, SAP303 Majority of Patients Had No Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TLPH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TLPH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TLPH▲ +5.1%on this news
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
Talphera, Inc. announced its first quarter 2026 financial results, highlighting significant progress in its NEPHRO CRRT clinical study, which is expected to complete later this year. The company reported a cash balance of $21.1 million and discussed the potential of nafamostat as an alternative anticoagulant for Continuous Renal Replacement Therapy. Despite a net loss of $2.6 million, the company remains optimistic about its product's market potential.
Read more →TLPHTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
Talphera, Inc. will announce its first quarter 2026 financial results on May 13, 2026, followed by a live webcast and conference call. Investors can dial in to participate in the discussion of the results and business updates. Talphera's lead product, Niyad®, is recognized for its potential as an anticoagulant and has received Breakthrough Device Designation from the FDA, highlighting the company's focus on innovative therapies.
Read more →TLPH▲ +9.1%on this news
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
Talphera, Inc. announced the acceptance of two abstracts for presentation at the AKI & CRRT 2026 conference. The studies focus on the safety and efficacy of nafamostat, a novel regional anticoagulant, in patients undergoing continuous renal replacement therapy. The NEPHRO-CRRT study aims to address unmet medical needs in this area, with promising early results.
Read more →TLPHTalphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Talphera, Inc. reported its fourth quarter and full year 2025 financial results, highlighting a significant milestone with 50% enrollment in the NEPHRO CRRT clinical study. The company has a strong cash position of $20.4 million and is hosting a virtual investor day to discuss the study's progress and the potential of nafamostat. The study aims to evaluate nafamostat's efficacy as an anticoagulant in renal replacement therapy.
Read more →TLPH▼ -8.2%on this newsshared move
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
Talphera, Inc. will host a virtual investor and analyst event on March 23, 2026, to discuss its product candidate Niyad for continuous renal replacement therapy (CRRT). The event will feature principal investigators from the NEPHRO CRRT study, which evaluates Niyad's efficacy as an anticoagulant. The study aims to address limitations of current anticoagulants like heparin and citrate, particularly for patients at risk of bleeding.
Read more →TLPHTalphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
Talphera, Inc. has announced that it has reached a 50% enrollment milestone in its NEPHRO-CRRT clinical trial, enrolling 35 out of 70 patients. The company has made significant changes to the trial, including a reduction in the total number of patients and updated enrollment criteria. Talphera plans to file for PMA this year, aiming to be the first FDA-approved regional anticoagulant for CRRT. A virtual investor event is scheduled for March 23, 2026, featuring expert nephrologists.
Read more →TLPH▼ -18.6%on this news
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Talphera, Inc. announced its third quarter 2025 financial results, highlighting a $17 million financing led by CorMedix. The company expects sufficient cash to support its Niyad PMA approval anticipated in late 2026. Five out of nine clinical sites for the NEPHRO study are now activated, with completion expected in the first half of 2026. The company will hold a conference call on November 12, 2025, to discuss these results further.
Read more →TLPH▼ -8.7%on this news
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
Talphera, Inc. will announce its third quarter 2025 financial results on November 12, 2025. Following the release, the company will host a live webcast and conference call to discuss the results and provide a business update. The webcast will include a slide presentation and be available for replay for 90 days. Talphera's lead product candidate has received Breakthrough Device Designation from the FDA.
Read more →TLPHTalphera Announces the Appointment of Joe Todisco to Board of Directors
Talphera, Inc. has appointed Joe Todisco, CEO of CorMedix, to its Board of Directors. This move follows CorMedix's strategic investment in Talphera, providing them the right to nominate a board member. Todisco expressed optimism about Talphera's lead product, Niyad, which aims to become a new standard of care for anticoagulation in CRRT.
Read more →TLPH▲ +45%on this news· ran to +76% by day 3
Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
Talphera, Inc. has announced a private placement financing of up to $29 million, led by CorMedix and supported by existing stockholders and new institutional investors. The first closing is expected to raise $17 million, with an additional $12 million contingent on achieving a primary endpoint in the NEPHRO clinical study. This funding aims to support Talphera through the anticipated approval of its Niyad PMA in late 2026.
Read more →TLPH▲ +17.3%on this news
Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial
Talphera, Inc. has announced the enrollment of 17 patients in its pivotal NEPHRO CRRT clinical trial, marking a significant milestone. The trial is on track for completion by the end of 2025, aided by an accelerated recruitment rate from new clinical sites. The study aims to evaluate the efficacy of Niyad, a formulation of nafamostat, in patients undergoing renal replacement therapy.
Read more →TLPHTalphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Talphera, Inc. announced its second quarter 2025 financial results and provided an update on its NEPHRO clinical study, reporting that 15 patients have been enrolled. The company is on track for study completion by year-end 2025 and anticipates increasing the number of clinical sites to 13 to enhance enrollment. Financial results show a net loss of $3.5 million for the quarter, an improvement compared to $3.8 million in the same period last year. Talphera also provided guidance for 2025 operating expenses, estimating between $16 million to $17 million.
Read more →TLPHTalphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025
Talphera, Inc. will release its second quarter financial results on August 14, 2025, after market close. Following the release, the company will conduct a live webcast and conference call to discuss the results and provide business updates. The event can be accessed via the company's website, and a replay will be available for 90 days. Talphera focuses on innovative therapies with its lead product candidate, Niyad™, currently under investigation as an anticoagulant and designated as a Breakthrough Device by the FDA.
Read more →TLPHTalphera Announces First Quarter 2025 Financial Results and Provides Corporate Update
Talphera, Inc. has reported its first quarter 2025 financial results and provided updates on its ongoing clinical initiatives. The company has activated three new clinical study sites in its NEPHRO CRRT study and anticipates five additional sites by mid-year. They received FDA approval to amend their study protocol, reducing the target patient enrollment to 70. Financially, Talphera closed a $4.4 million financing tranche, but reported a net loss of $2.6 million for the quarter, highlighting the ongoing challenges they face in terms of operational costs.
Read more →TLPHTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025
Talphera, Inc. will announce its first quarter 2025 financial results on May 14, 2025, followed by a live webcast and conference call. This event aims to provide investors with insights into the company’s performance and updates on its business operations. The conference will also cover details about their lead product candidate, Niyad™, which is under investigation for anticoagulant use and has received Breakthrough Device Designation from the FDA.
Read more →TLPH▼ -15.5%on this news
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Talphera, Inc. announced its fourth-quarter and full-year 2024 financial results, highlighting several key developments. Significant news included the FDA's approval to reduce the patient count in the NEPHRO CRRT study and a new financing agreement for $14.8 million. Talphera aims to complete the NEPHRO study by the end of 2025, supported by new clinical sites. However, the company reported a net loss of $1.9 million for Q4 2024, marking a decrease from the previous year's loss.
Read more →TLPH▼ -15.5%on this news
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million
Talphera, Inc. has announced an agreement with the FDA to reduce the patient size for its NEPHRO CRRT study from 166 to 70, with 6 patients already enrolled. The company expects to complete the study by the end of 2025 and has initiated a private placement financing aiming to raise up to $14.8 million, with initial gross proceeds of $4.925 million expected. The financing is contingent on achieving certain milestones in patient enrollment and stock price performance. CEO Vince Angotti expressed optimism regarding the study's potential and the support from existing investors.
Read more →TLPHTalphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
Talphera, Inc. will announce its fourth quarter and full-year 2024 financial results after market close on March 31, 2025. Following the announcement, the company will host a live webcast and conference call to discuss the results and provide a business update. Talphera's lead product candidate has received Breakthrough Device Designation from the FDA, indicating its potential significance in the market.
Read more →TLPHTalphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
Talphera, Inc. announced that the FDA has agreed to review a Prior Approval Supplement aimed at reducing patient numbers in the NEPHRO CRRT study. The FDA also approved two additional protocol changes, which are expected to accelerate patient enrollment. Talphera is focused on completing the study by the end of 2025 and is confident in its product candidate Niyad, which has received Breakthrough Device Designation from the FDA.
Read more →TLPHTalphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Talphera, Inc. reported its third quarter 2024 financial results, highlighting progress in its NEPHRO CRRT study, which has commenced patient screening at five active clinical sites, with two additional sites expected to begin in the fourth quarter. The company has $11.1 million in cash and investments as of September 30, 2024, though it incurred a net loss of $3.4 million during the quarter, attributed to increased research and development costs. Talphera remains optimistic about nafamostat as a potential FDA-approved alternative anticoagulant, following positive engagements with healthcare professionals and progress in enrollment strategies for the study.
Read more →TLPHTalphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
Talphera, Inc. announced it will release its third quarter 2024 financial results on November 13, 2024. Following the results, the company will host a live webcast and conference call to discuss its performance and provide a corporate update. The webcast will be accessible on Talphera's website, and a replay will be available for 90 days. The company is known for its lead product candidate, Niyad™, which is being studied as an anticoagulant and has received FDA Breakthrough Device Designation.
Read more →TLPHTalphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Talphera, Inc. will participate in the 2024 Maxim Healthcare Virtual Summit, scheduled for October 15-17, 2024. During the summit, management will engage in a fireside chat and hold one-on-one meetings with registered investors. The event reflects Talphera's ongoing commitment to transparency and investor relations. The company is recognized for its innovative therapies, particularly its lead product candidate Niyad™, which has received FDA Breakthrough Device Designation as an anticoagulant.
Read more →TLPH▲ +5.6%on this news
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Talphera, Inc. has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, to be held from September 9-11, 2024, in New York City. The company will engage in one-on-one meetings and make a presentation available on-demand. Talphera focuses on developing innovative therapies, notably Niyad™, an anticoagulant currently under investigation and designated as a Breakthrough Device by the FDA, underscoring its potential importance in medical settings.
Read more →TLPHTalphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
Talphera, Inc. has announced the enrollment of the first patient in its NEPHRO CRRT registrational trial evaluating nafamostat for anticoagulation in patients undergoing continuous renal replacement therapy. Conducted across 14 clinical sites in the U.S., the trial aims to enroll 166 patients and assess the mean post-filter activated clotting time over the initial 24 hours. Nafamostat, already a standard treatment in Japan and South Korea, is being studied for its potential advantages in addressing the current shortcomings of anticoagulation products available in the U.S.
Read more →TLPH▼ -5.5%on this newsshared move
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Talphera, Inc. has released its financial results for the second quarter of 2024, announcing the initiation of patient screening for the NEPHRO CRRT study at multiple clinical sites. The company has received FDA approval to expand the number of study sites, enhancing the study's scope. CEO Vince Angotti expressed optimism regarding the potential for expedited completion and approval of their product candidate, nafamostat. The financial results highlighted a slight increase in net loss compared to the prior year, alongside rising operational expenses.
Read more →TLPHTalphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024
Talphera, Inc. announced it will release its second quarter 2024 financial results on August 14, 2024. Following the results, a live webcast and conference call will be held to discuss the financial outcomes and provide updates on the company's business. Talphera is focused on the development of innovative therapies, including its lead product candidate, Niyad™, which has received Breakthrough Device Designation from the FDA. Investors can access the webcast through the company’s website after release.
Read more →TLPHTalphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Talphera, Inc. has granted inducement equity awards to Dr. Shakil Aslam, its newly appointed Chief Development Officer, as part of its compliance with Nasdaq Listing Rule 5635(c)(4). The awards include options to purchase 185,000 shares and restricted stock units for 32,000 shares, with specific vesting schedules based on continued employment. Talphera focuses on innovative therapies, with its lead candidate Niyad™ currently undergoing clinical studies as an anticoagulant and has received FDA's Breakthrough Device Designation. This move underlines Talphera's strategy to strengthen its leadership team and advance its therapeutic developments.
Read more →TLPH▼ -5.3%on this newsshared move
Talphera to Participate at A.G.P. Virtual Healthcare Conference
Talphera, Inc. has announced its participation in the A.G.P. Virtual Healthcare Conference on May 21, 2024, during which management will engage in a fireside chat. This event is an opportunity for the company to communicate updates regarding its innovative therapies, including its lead product candidate, Niyad™, which has received Breakthrough Device Designation from the FDA. Talphera specializes in developing therapies for medically supervised settings, with additional products in the pipeline.
Read more →TLPHTalphera Announces First Quarter 2024 Financial Results and Provides Corporate Update
Talphera, Inc. reported its financial results for the first quarter of 2024, highlighting the anticipated enrollment of first patients in the NEPHRO CRRT registrational study by Q2 2024. The company announced a recent cash balance of $18.6 million and the hiring of Dr. Shakil Aslam as Chief Development Officer, who brings extensive experience in nephrology. However, Talphera acknowledged delays in trial site activations, which may impact their projected timeline for top-line data. The company also reported a net loss of $4 million compared to a net income in the same quarter last year.
Read more →TLPHTalphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024
Talphera, Inc. has announced its upcoming financial results release for the first quarter of 2024, scheduled after market close on May 14, 2024. The company will host a live webcast and conference call to discuss the results earlier that day. This event will be accessible via Talphera's website and is part of their commitment to keeping investors informed about their business and product developments. Talphera continues to focus on innovative therapies, including their lead product candidate, Niyad, which has received notable FDA recognition.
Read more →TLPHTalphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
Talphera, Inc. announced its fourth-quarter financial results for 2023 and highlighted its corporate transformation. The company's rebranding from AcelRx Pharmaceuticals has aimed to streamline its focus on innovative therapies, particularly Niyad, an anticoagulant currently under development. With $9.4 million in cash and investments, Talphera anticipates a significant upcoming milestone with the NEPHRO CRRT registrational study set to begin in Q1 2024 and a PMA submission planned by the end of 2024. Despite ongoing net losses, the financial updates reveal a commitment to substantial growth and development in the coming years.
Read more →TLPHTalphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
Talphera, Inc. has announced a reduction in its Board of Directors from ten members to seven, as part of its commitment to corporate governance best practices. The resignations of directors Howard Rosen, Richard Afable, and Pamela Palmer are effective immediately, though Dr. Palmer will remain as Chief Medical Officer. Chairman Adrian Adams emphasized that this move aims to improve the board's efficiency in pursuing FDA approval for the Niyad product candidate, which has received Breakthrough Device Designation from the FDA. The company believes that the remaining board members possess the necessary expertise to navigate future challenges.
Read more →TLPHTalphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024
Talphera, Inc. has announced the upcoming release of its fourth quarter and full-year 2023 financial results on March 6, 2024. Following the announcement, a live webcast and conference call will be held to discuss the results and provide a business update. Investors can participate in the call, with dial-in options provided for North American and international callers. Talphera's lead product candidate has received FDA Breakthrough Device Designation, further indicating the company's innovative focus.
Read more →TLPH▲ +26%on this news· ran to +43% by day 3
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
Talphera, Inc. announced a commitment of $26 million in funding to support its operations through a potential FDA approval of its lead candidate, Niyad, expected in the first half of 2025. The capital includes $16 million from equity offerings and $8 million through the monetization of DSUVIA royalties. Furthermore, additional funding may be realized upon the announcement of positive trial results for the NEPHRO registration. The company aims to advance its pivotal study while securing necessary capital to sustain operations until its expected market entry.
Read more →TLPHAcelRx Announces Rebranding With Name Change to Talphera, Inc.
AcelRx Pharmaceuticals, Inc. has announced its rebranding to Talphera, Inc., effective January 10, 2024. This change signals the company's shift from focusing solely on acute pain treatments to a broader mission of developing innovative therapies for medically supervised settings. Talphera's lead product candidate, Niyad, is in the process of gaining Premarket Approval with significant studies planned. The rebranding reflects a commitment to enhance patient outcomes and optimize care delivery.
Read more →TLPHAcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase Under revised terms, AcelRx to acquire Tetraphase for $37.0 million in stock and cash plus CVRs Continues to believe the Tetraphase acquisition co
AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase Under revised terms, AcelRx to acquire Tetraphase for $37.0 million in stock and cash plus CVRs Continues to believe the Tetraphase acquisition complements AcelRx s commercial strategy and will deliver lo
Read more →TLPHAcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase Under revised terms, AcelRx to acquire Tetraphase for $30.0 million in stock and cash, plus an additional $14.5 million in CVRs Continues to belie
AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase Under revised terms, AcelRx to acquire Tetraphase for $30.0 million in stock and cash, plus an additional $14.5 million in CVRs Continues to believe Tetraphase acquisition complements AcelRx s commercial
Read more →TLPHAcelRx Announces DSUVIA Milestone C Approval and Provides Business Update Milestone C decision clears the way for the military to begin procuring
AcelRx Announces DSUVIA Milestone C Approval and Provides Business Update Milestone C decision clears the way for the military to begin procuring DSUVIA REDWOOD CITY, Calif., April 30, 2020 AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical compan
Read more →TLPHAcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., August 1, 2017 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization o
Read more →TLPHAcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer REDWOOD CITY, Calif., July 19, 2017 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treat
Read more →TLPHEvent ID: Event Name: ACRX - AcelRx 1Q17 Financial Results Event Date: 2017-05-08 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO and Head of Business Development Jane Wright-Mitchell; AcelRx Pharmace
Event Name: ACRX - AcelRx 1Q17 Financial Results Event Date: 2017-05-08 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO and Head of Business Development Jane Wright-Mitchell; AcelRx Pharmaceuticals, Inc.; Chief Legal Officer Vince Angotti; AcelRx Pharmace
Read more →TLPHEvent ID: Event Name: ACRX - AcelRx 4Q16 and FY16 Financial Results Event Date: 2017-03-02 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO and Head of Business Development Jane Wright-Mitchell; AcelRx
Event Name: ACRX - AcelRx 4Q16 and FY16 Financial Results Event Date: 2017-03-02 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO and Head of Business Development Jane Wright-Mitchell; AcelRx Pharmaceuticals, Inc.; Chief Legal Officer. Howie Rosen; AcelRx
Read more →TLPHAcelRx Pharmaceuticals Submits New Drug Application for ARX-04 for the Treatment of Moderate-To-Severe Acute Pain
AcelRx Pharmaceuticals Submits New Drug Application for ARX-04 for the Treatment of Moderate-To-Severe Acute Pain REDWOOD CITY, Calif., December 13, 2016 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercializ
Read more →TLPHEvent ID: Event Name: ACRX - AcelRx 3Q16 Results Call Event Date: 2016-11-01 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO and Head of Business Development Jane Wright-Mitchell; AcelRx Pharmaceutica
Event Name: ACRX - AcelRx 3Q16 Results Call Event Date: 2016-11-01 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO and Head of Business Development Jane Wright-Mitchell; AcelRx Pharmaceuticals, Inc.; Chief Legal Officer. Howie Rosen; AcelRx Pharmaceutical
Read more →TLPHAcelRx Conference Call September-15-2016 Confirmation #13645416 Page 1 AcelRx Pharmaceuticals, Inc. Positive Phase 3 Data Results September-15-2016 Confirmation #13645416 Operator: Greetings, and welcome to the AcelRx Po
AcelRx Conference Call Confirmation #13645416 AcelRx Pharmaceuticals, Inc. Positive Phase 3 Data Results Confirmation #13645416 Operator: Greetings, and welcome to the AcelRx Positive Phase 3 Data Results. At this time, all participants are in a listen-only mode. A brief qu
Read more →TLPHAcelRx Reports Positive Results for ARX-04 (sufentanil sublingual tablet, 30 mcg), Including in Elderly Patients and Patients with Organ Impairment, in Third Phase 3 Registration Trial, SAP303 Majority of Patients Had No
AcelRx Reports Positive Results for ARX-04 (sufentanil sublingual tablet, 30 mcg), Including in Elderly Patients and Patients with Organ Impairment, in Third Phase 3 Registration Trial, SAP303 REDWOOD CITY, California, September 15, 2016 - AcelRx Pharmaceuticals, Inc. (NASDAQ: A
Read more →TLPHEvent ID: Event Name: ACRX - AcelRx Second Quarter 2016 Financial Results Event Date: 2016-07-28 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO and Head of Business Development Jane Wright-Mitchell;
Event Name: ACRX - AcelRx Second Quarter 2016 Financial Results Event Date: 2016-07-28 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO and Head of Business Development Jane Wright-Mitchell; AcelRx Pharmaceuticals, Inc.; Chief Legal Officer. Howie Rosen; A
Read more →TLPHEvent ID: Event Name: [ACRX] - AcelRx Q1 Results Call Event Date: 2016-05-02 Officers and Speakers Timothy Morris; AcelRx Pharmaceuticals, Inc.; CFO and Head of Business Development Howie Rosen; AcelRx Pharmaceuticals, I
Event Name: [ACRX] - AcelRx Q1 Results Call Event Date: 2016-05-02 Officers and Speakers Timothy Morris; AcelRx Pharmaceuticals, Inc.; CFO and Head of Business Development Howie Rosen; AcelRx Pharmaceuticals, Inc.; CEO Pamela Palmer; AcelRx Pharmaceuticals, Inc.; Co-Founder
Read more →TLPHEvent ID: Event Name: [ACRX] - AcelRx Conference Call Event Date: 2016-03-29 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO Howie Rosen; AcelRx Pharmaceuticals, Inc.; CEO Pamela Palmer; AcelRx Pharma
Event Name: [ACRX] - AcelRx Conference Call Event Date: 2016-03-29 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO Howie Rosen; AcelRx Pharmaceuticals, Inc.; CEO Pamela Palmer; AcelRx Pharmaceuticals, Inc.; Founder and Chief Medical Officer Jane Wright-M
Read more →TLPHEvent ID: Event Name: AcelRx Pharmaceuticals Annual 2015 Financial Results Event Date: 2016-03-07 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO, Head of Business Development Howie Rosen; AcelRx Phar
Event Name: AcelRx Pharmaceuticals Annual 2015 Financial Results Event Date: 2016-03-07 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO, Head of Business Development Howie Rosen; AcelRx Pharmaceuticals, Inc.; Interim CEO Pamela Palmer; AcelRx Pharmaceutic
Read more →TLPHAcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso in 1Q 2016
AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso in 1Q 2016 REDWOOD CITY, Calif., January 8, 2016 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commerc
Read more →TLPHAcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04 - AcelRx Anticipates the Submission of the ARX-04 New Drug Application in the Second Half of 2016 -
AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04 - AcelRx Anticipates the Submission of the ARX-04 New Drug Application in the Second Half of 2016 - FDA Agrees to Include a Significant Number of Patients from the Zalviso Studies
Read more →TLPHEvent ID: Event Name: [ACRX] - AcelRx 3Q15 Financial Results Event Date: 2015-10-29 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO Howie Rosen; AcelRx Pharmaceuticals, Inc.; Interim CEO Pamela Palmer
Event Name: [ACRX] - AcelRx 3Q15 Financial Results Event Date: 2015-10-29 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO Howie Rosen; AcelRx Pharmaceuticals, Inc.; Interim CEO Pamela Palmer; AcelRx Pharmaceuticals, Inc.; Co-Founder & Chief Medical Office
Read more →TLPHAcelRx Pharmaceuticals Provides Business Update and Reports Third Quarter and Nine Months 2015 Financial Results
AcelRx Pharmaceuticals Provides Business Update and Reports Third Quarter and Nine Months 2015 Financial Results REDWOOD CITY, Calif., October 29, 2015 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercializat
Read more →TLPHAcelRx Pharmaceuticals Provides Regulatory Update on Zalviso REDWOOD CITY, Calif., October 8 , 2015 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the d
AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso REDWOOD CITY, Calif., October 8, 2015 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acut
Read more →TLPHAcelRx Pharmaceuticals Reports that the European Commission has Granted Marketing Authorization for Zalviso for Treatment of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients Approval triggers $15 million mi
AcelRx Pharmaceuticals Reports that the European Commission has Granted Marketing Authorization for Zalviso for Treatment of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients Approval triggers $15 million milestone payment to AcelRx from Grunenthal REDWOOD CITY, Ca
Read more →TLPHAcelRx Pharmaceuticals ARX-04 Meets all Endpoints in Pivotal Phase 3 Study for Moderate-to-Severe Acute Pain Detailed SAP301 Results to be Presented at the American Society of Anesthesiologists Annual Meeting October 24-
AcelRx Pharmaceuticals' ARX-04 Meets all Endpoints in Pivotal Phase 3 Study for Moderate-to-Severe Acute Pain Detailed SAP301 Results to be Presented at the American Society of Anesthesiologists Annual Meeting October 24-28, 2015 in San Diego, CA. REDWOOD CITY, Calif. -- Septem
Read more →TLPHEvent ID: Event Name: [ACRX] - AcelRx 2Q15 Financial Results Event Date: 2015-08-03 Officers and Speakers Timothy Morris; AcelRx Pharmaceuticals, Inc.; CFO & Head of Business Development Howie Rosen; AcelRx Pharmaceutica
Event Name: [ACRX] - AcelRx 2Q15 Financial Results Event Date: 2015-08-03 Officers and Speakers Timothy Morris; AcelRx Pharmaceuticals, Inc.; CFO & Head of Business Development Howie Rosen; AcelRx Pharmaceuticals, Inc.; Interim CEO Pam Palmer; AcelRx Pharmaceuticals, Inc.; C
Read more →TLPHAcelRx Announce s Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to- Severe Post-Operative Pain in Adult Patients REDWOOD CITY, Calif. - DATE - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx)
AcelRx Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients REDWOOD CITY, Calif. - DATE - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) announced today that the Committee for Medicinal Products fo
Read more →TLPHAcelRx Pharmaceuticals First Quarter 2015 Financial Results
AcelRx Pharmaceuticals First Quarter 2015 Financial Results May 4, 2015 @ 4:30 pm Eastern CORPORATE PARTICIPANTS Tim Morris - Chief Financial Officer Howie Rosen - interim Chief Executive Officer Pamela Palmer -Co-Founder and Chief Medical Officer Good afternoon and welcome to t
Read more →TLPHEvent ID: Event Name: [ACRX] - AcelRx Fourth Quarter and Annual Financial Results Event Date: 2015-03-09 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO Richard King; AcelRx Pharmaceuticals, Inc.; Pre
Event Name: [ACRX] - AcelRx Fourth Quarter and Annual Financial Results Event Date: 2015-03-09 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO Richard King; AcelRx Pharmaceuticals, Inc.; President & CEO Pam Palmer; AcelRx Pharmaceuticals, Inc.; Co-Founder
Read more →TLPHForward Looking Statements 2 This presentation contains forward looking statements, including, but not limited to, statements related to future financial results, potential proceeds under the Grunenthal agreement, the pr
Sponsored by AcelRx Pharmaceuticals, Inc. 0% 20% 40% 60% 80% Physician Stated Share 25 Scientific Conference Schedule 2015 Minimally Invasive Surgery Symposium (MISS) February 25 28; Las Vegas, NV poster presentation (ARX 04) American Academy of Orthopedic Surgeons (AAOS) March 2
Read more →TLPHJanuary 2015 Forward Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to future financial results, potential proceeds under the Grunenthal agreem
Forward Looking Statements contains forward-looking statements, including, but not limited to, statements related to future financial results, potential proceeds under the Grunenthal agreement, the process and timing of anticipated future development of AcelRx s product candida
Read more →TLPHEvent ID: Event Name: [ACRX] - AcelRx Q3 Financial Results Event Date: 2014-11-10 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO Adrian Adams; AcelRx Pharmaceuticals, Inc.; Chairman Richard King; Ace
Event Name: [ACRX] - AcelRx Q3 Financial Results Event Date: 2014-11-10 Officers and Speakers Tim Morris; AcelRx Pharmaceuticals, Inc.; CFO Adrian Adams; AcelRx Pharmaceuticals, Inc.; Chairman Richard King; AcelRx Pharmaceuticals, Inc.; President & CEO Louise Chen, Guggenhe
Read more →TLPHAcelRx Pharmaceuticals Reports Third Quarter 2014 Financial Results
AcelRx Pharmaceuticals Reports Third Quarter 2014 Financial Results REDWOOD CITY, Calif., November 10, 2014 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the
Read more →TLPHAcelRx Pharmaceuticals Provides Regulatory Update on Zalviso
AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso REDWOOD CITY, Calif., September 26, 2014 /PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the tr
Read more →TLPHAcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso
AcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso REDWOOD CITY, Calif., July 25, 2014 /PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercializat
Read more →TLPHAcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer
AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer CA March 25, 2014 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and
Read more →TLPHAcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results REDWOOD CITY, Calif., March 3, 2014 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for th
Read more →TLPHAcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital
AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital REDWOOD CITY, Calif., December 19, 2013 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies fo
Read more →TLPHAcelRx and Gr nenthal Announce Collaboration for EU Commercialization of ZALVISO TM - FDA establishes the PDUFA action date of
AcelRx and Gr nenthal Announce Collaboration for EU Commercialization of ZALVISOTM - FDA establishes the PDUFA action date of July 27, 2014 for Zalviso - - Conference Call Scheduled Monday, December 16th 2013 for 8:30 a.m. Eastern Time Redwood City, California and Aachen, Ger
Read more →TLPHAcelRx Pharmaceuticals Adds New Board Member
AcelRx Pharmaceuticals Adds New Board Member REDWOOD CITY, Calif., December 11, 2013 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthro
Read more →TLPHAcelRx Pharmaceuticals Submits New Drug Application to the FDA for Zalviso Zalviso NDA submitted for the management of moderate-to-severe acute pain in adult patients in the hospital setting
AcelRx Pharmaceuticals Submits New Drug Application to the FDA for Zalviso Zalviso NDA submitted for the management of moderate-to-severe acute pain in adult patients in the hospital setting REDWOOD CITY, Calif., September 30, 2013 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX),
Read more →TLPHForward-Looking Statements This Current Report on Form 8-K, or Form 8-K, contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, whic
Forward-Looking Statements This Current Report on Form 8-K, or Form 8-K, contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the safe harbor created by that section.
Read more →TLPHAcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results REDWOOD CITY, Calif., May 8, 2013 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ( AcelRx ), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the tre
Read more →TLPHAcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
1 AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results REDWOOD CITY, Calif., March 12, 2013 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ( AcelRx ), a specialty pharmaceutical company focused on the development and commercialization of innovative t
Read more →TLPHAcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients - Patients experienced
AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients Patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p=0.00
Read more →TLPHAcelRx Appoints Adrian Adams to Board of Directors as Chairman
AcelRx Appoints Adrian Adams to Board of Directors as Chairman REDWOOD CITY, Calif., February 12, 2013 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of a
Read more →TLPHRISK FACTORS Our business is subject to various risks, including those described below. You should carefully consider these risk factors, together with all of the other information included in our Annual Report on Form 1
Our business is subject to various risks, including those described below. You should carefully consider these risk factors, together with all of the other information included in our Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10
Read more →TLPHAcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab PCA System vs. IV PCA Morphine for Post-Operative Pain -In this open-label study, the Sufentan
AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab PCA System vs. IV PCA Morphine for Post-Operative Pain -In this open-label study, the Sufentanil NanoTab PCA System also demonstrated statistical superiority to IV PCA morphin
Read more →TLPHAcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results REDWOOD CITY, Calif., November 6, 2012 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment
Read more →TLPHAcelRx Pharmaceuticals Initiates Third Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab PCA System, for the Treatment of Post-Operative Pain First orthopedic surgery patient dosed in randomized, dou
AcelRx Pharmaceuticals Initiates Third Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab PCA System, for the Treatment of Post-Operative Pain First orthopedic surgery patient dosed in randomized, double-blind, placebo-controlled trial REDWOOD CITY, Calif., Aug. 23, 201
Read more →TLPHAcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results Calif., August 9, 2012 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ( AcelRx ), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of a
Read more →TLPHAcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms Two new U.S. patents expand intellectual property protection for AcelRx pipeline of sufent
AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms Two new U.S. patents expand intellectual property protection for AcelRx pipeline of sufentanil NanoTab pain products REDWOOD CITY, Calif., August 1, 2012 AcelRx Pharma
Read more →TLPHAcelRx Pharmaceuticals Completes Private Placement of $10.0 Million
AcelRx Pharmaceuticals Completes Private Placement of $10.0 Million Calif., June 4, 2012 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and brea
Read more →TLPHAcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing Calif., May 30, 2012 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute a
Read more →TLPHAcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results REDWOOD CITY, Calif., May 8, 2012 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ( AcelRx ), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the tre
Read more →TLPHAcelRx Pharmaceuticals Receives Two Notices of Allowance for Small-Volume Oral Transmucosal Dosage Forms First US allowances could provide for intellectual property protection for AcelRx pipeline of
AcelRx Pharmaceuticals Receives Two Notices of Allowance for Small-Volume Oral Transmucosal First US allowances could provide for intellectual property protection for AcelRx pipeline of NanoTab pain products until at least 2029. April 11, 2012 AcelRx Pharmaceuticals, Inc. (AC
Read more →TLPHAcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results REDWOOD CITY, Calif., March 20, 2012 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ( AcelRx ), a specialty pharmaceutical company focused on the development and commercialization of innovative the
Read more →TLPHAcelRx Pharmaceuticals Reports Third Quarter 2011 Financial Results
AcelRx Pharmaceuticals Reports Third Quarter 2011 Financial Results REDWOOD CITY, Calif., November 8, 2011 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ( AcelRx ), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for th
Read more →TLPHAcelRx Pharmaceuticals Appoints Mark G. Edwards To Its Board of Directors
AcelRx Pharmaceuticals Appoints Mark G. Edwards To Its Board of Directors REDWOOD CITY, Calif., September 28, 2011 AcelRx Pharmaceuticals, Inc., (NASDAQ: ACRX) ( AcelRx ), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie
Read more →TLPHAcelRx Pharmaceuticals Reports Second Quarter 2011 Financial Results Remains On Track to Initiate First ARX-01 Phase 3 Clinical Trial Later This Year
AcelRx Pharmaceuticals Reports Second Quarter 2011 Financial Results Remains On Track to Initiate First ARX-01 Phase 3 Clinical Trial Later This Year REDWOOD CITY, Calif., August 11, 2011 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ( AcelRx ), a specialty pharmaceutical compan
Read more →TLPHAcelRx Secures $20 Million Loan Financing Agreement, Expected to Extend Its Operating Cash Runway Into 2013
AcelRx Secures $20 Million Loan Financing Agreement, Expected to Extend Its Operating Cash Runway Into 2013 REDWOOD CITY, Calif., June 30, 2011 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx) today announced that it has obtained a $20 million secured loan agreement with Her
Read more →TLPHAcelRx Announces $5.6 Million Department of Defense Grant to Develop ARX-04, a New Acute Pain Product Candidate
AcelRx Announces $5.6 Million Department of Defense Grant to Develop ARX-04, a New Acute Pain Product Candidate REDWOOD CITY, Calif., May 31, 2011 /PRNewswire via COMTEX/ AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)(AcelRx), today announced that the US Army Medical Research and
Read more →TLPHAcelRx Pharmaceuticals Reports First Quarter 2011 Financial Results Initiation of Phase 3 Trial for Lead Product Candidate ARX-01 On Track for Second Half of 2011
AcelRx Pharmaceuticals Reports First Quarter 2011 Financial Results Initiation of Phase 3 Trial for Lead Product Candidate ARX-01 On Track for Second Half of 2011 REDWOOD CITY, Calif., May 12, 2011 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ( AcelRx ), a specialty pharmaceuti
Read more →TLPHAcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results Plans to Initiate the Phase 3 Program for Lead Product Candidate ARX-01 in Second Half of 2011; IPO Completed
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results Plans to Initiate the Phase 3 Program for Lead Product Candidate ARX-01 in Second Half of 2011; REDWOOD CITY, Calif., March 24, 2011 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ( AcelRx ), a sp
Read more →Competitive Position
How TLPH ranks across every disease it competes inCompetitive Position is a premium feature
See how TLPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial